Site search
2831 results for '' found
Aneurysmal Subarachnoid Hemorrhage -Red Blood Cell Transfusion and Outcome (SAHaRA): A Randomized Controlled Trial. (NCT03309579)
Aneurysmal Subarachnoid Hemorrhage -Red Blood Cell Transfusion and Outcome (SAHaRA): A Randomized Controlled Trial. (NCT03309579)
/
Secondary Access - FEmoral or radial in Transcatheter Aortic Valve Implantation TAVI? (NCT06284837)
Secondary Access - FEmoral or radial in Transcatheter Aortic Valve Implantation TAVI? (NCT06284837)
/
A phase III randomised controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) of Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer. (NCT03862911)
A phase III randomised controlled trial and economic evaluation of Stereotactic Ablative Radiotherapy (SABR) of Comprehensive treatment of OligoMETastatic (1-3 metastases) cancer. (NCT03862911)
/
Selective Serotonin Reuptake Inhibitors And Depression in Atrial Fibrillation (SAD-AF) (ACTRN12623000227695p)
Selective Serotonin Reuptake Inhibitors And Depression in Atrial Fibrillation (SAD-AF) (ACTRN12623000227695p)
/
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of 4-10 Oligometastatic Tumors (SABR-COMET 10) (NCT03721341)
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of 4-10 Oligometastatic Tumors (SABR-COMET 10) (NCT03721341)
/
A Phase 3, multicentre, randomized, double-blind, placebo controlled study of oral ozanimod as maintenance therapy for moderately to severely active Crohn’s disease (RPC01-3203) (NCT03464097)
A Phase 3, multicentre, randomized, double-blind, placebo controlled study of oral ozanimod as maintenance therapy for moderately to severely active Crohn’s disease (RPC01-3203) (NCT03464097)
/
A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease (Celgene 3202) (NCT03440385)
A Phase 3, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease (Celgene 3202) (NCT03440385)
/
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease (NCT03467958)
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease (NCT03467958)
/
INDUCTION STUDY #1 - A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE (NCT03440372
INDUCTION STUDY #1 - A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS INDUCTION THERAPY FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE (NCT03440372
/
Red Blood Cell Transfusion in ECMO - a feasibility trial (NCT05814094)
Red Blood Cell Transfusion in ECMO - a feasibility trial (NCT05814094)
/